Calliditas Therapeutics AB (publ) (CALTX.ST)
SEK 208.0
(0.87%)
SEK 208.0
(0.87%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 939.5 Million SEK | 28.91% |
| 2022 | 728.82 Million SEK | 241.82% |
| 2021 | 213.21 Million SEK | 24184.28% |
| 2020 | 878 Thousand SEK | -75.5% |
| 2019 | 3.58 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1.01 Billion SEK | 4.99% |
| 2024 Q2 | 982.48 Million SEK | -0.4% |
| 2023 FY | 939.5 Million SEK | 28.91% |
| 2023 Q3 | 770.16 Million SEK | -1.21% |
| 2023 Q2 | 779.56 Million SEK | 7.68% |
| 2023 Q1 | 723.99 Million SEK | -0.66% |
| 2023 Q4 | 939.5 Million SEK | 21.99% |
| 2022 Q2 | 458.02 Million SEK | 113.54% |
| 2022 FY | 728.82 Million SEK | 241.82% |
| 2022 Q1 | 214.49 Million SEK | 0.6% |
| 2022 Q3 | 467.31 Million SEK | 2.03% |
| 2022 Q4 | 728.82 Million SEK | 55.96% |
| 2021 Q1 | 1.31 Million SEK | 50.23% |
| 2021 FY | 213.21 Million SEK | 24184.28% |
| 2021 Q4 | 213.21 Million SEK | 13.76% |
| 2021 Q3 | 187.42 Million SEK | 5288.93% |
| 2021 Q2 | 3.47 Million SEK | 163.68% |
| 2020 Q1 | 2.33 Million SEK | -34.77% |
| 2020 Q2 | 1.67 Million SEK | -28.53% |
| 2020 FY | 878 Thousand SEK | -75.5% |
| 2020 Q4 | 878 Thousand SEK | -15.09% |
| 2020 Q3 | 1.03 Million SEK | -38.12% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 Q4 | 3.58 Million SEK | -14.87% |
| 2019 Q3 | 4.21 Million SEK | -13.46% |
| 2019 Q2 | 4.86 Million SEK | 0.0% |
| 2019 FY | 3.58 Million SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alzinova AB (publ) | 800 Thousand SEK | -117338.5% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -93850.8% |
| BioArctic AB (publ) | 2.15 Million SEK | -43557.435% |
| Genovis AB (publ.) | 74.8 Million SEK | -1155.892% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 32.58 Million SEK | -2783.519% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 65.23 Million SEK | -1340.124% |
| Simris Alg AB (publ) | 90.74 Million SEK | -935.385% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | 3 Million SEK | -31216.933% |
| Camurus AB (publ) | 13.61 Million SEK | -6801.55% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 850 Thousand SEK | -110430.353% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -53250.823% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xbrane Biopharma AB (publ) | 112.89 Million SEK | -732.182% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Ziccum AB (publ) | 286 Thousand SEK | -328399.301% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 31.94 Million SEK | -2840.833% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -2963.08% |
| Intervacc AB (publ) | 142 Thousand SEK | -661525.352% |
| Alligator Bioscience AB (publ) | 7.51 Million SEK | -12400.106% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 24.51 Million SEK | -3733.006% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 4.29 Million SEK | -21769.367% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -221482.075% |
| Egetis Therapeutics AB (publ) | 103.4 Million SEK | -808.615% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 844.9 Million SEK | -11.197% |
| Cyxone AB (publ) | 74 Thousand SEK | -1269505.405% |
| ExpreS2ion Biotech Holding AB (publ) | 1.43 Million SEK | -65325.348% |
| Biosergen AB | - SEK | -Infinity% |
| Nanologica AB (publ) | 136 Thousand SEK | -690714.706% |
| SynAct Pharma AB | 58 Thousand SEK | -1619741.379% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 14.53 Million SEK | -6363.763% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -110430.353% |
| Oncopeptides AB (publ) | 106.48 Million SEK | -782.275% |
| Pila Pharma AB (publ) | - SEK | -Infinity% |
| Ascelia Pharma AB (publ) | 176 Thousand SEK | -533711.364% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |